January 30, 2019
Savolitinib vs. Sunitinib in MET-driven PRCC
Read More
January 30, 2019
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC
Read More
January 30, 2019
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Read More
January 30, 2019
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Read More
January 30, 2019
An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
Read More
January 30, 2019
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Read More
January 30, 2019
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Read More
January 30, 2019
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Read More
January 30, 2019
A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma
Read More
Load More
X